These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28508753)

  • 1. Endometriosis in the setting of Muckle-Wells syndrome treated with an IL-1β antagonist.
    Sasaki-Saito N; Sawada Y; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Nishio D; Nakamura M
    Eur J Dermatol; 2017 Aug; 27(4):442-443. PubMed ID: 28508753
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of neonatal onset multisystem inflammatory disease supporting a role of interleukin-1β in moyamoya syndrome.
    Wohlrab F; Bauknecht C; Meisel C; Dreier JP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):e1-3. PubMed ID: 33109682
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.
    Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I
    Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update in interleukin-1 inhibition].
    de Boysson H
    Rev Med Interne; 2012 Apr; 33(4):235-7. PubMed ID: 22360831
    [No Abstract]   [Full Text] [Related]  

  • 7. Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene.
    Iida Y; Wakiguchi H; Okazaki F; Nakamura T; Yasudo H; Kubo M; Sugahara K; Yamashita H; Suehiro Y; Okayama N; Hashimoto K; Iwamoto N; Kawakami A; Aoki Y; Takada H; Ohga S; Hasegawa S
    Clin Rheumatol; 2019 Mar; 38(3):943-948. PubMed ID: 30338413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist].
    Rameev VV; Kozlovskaia LV; Bogdanova MV
    Ter Arkh; 2012; 84(6):53-9. PubMed ID: 22997920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muckle-Wells treatment with anakinra.
    Eungdamrong J; Boyd KP; Meehan SA; Latkowski JA
    Dermatol Online J; 2013 Dec; 19(12):20720. PubMed ID: 24365011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopyrin-associated periodic syndromes: diagnosis and management.
    Miyamae T
    Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Adult Patient With a Novel Mutation in NLRP3 Gene Associated With Cryopyrin-Associated Periodic Syndrome Mimicking Adult-Onset Still Disease.
    Ocampo V; Ortiz-Sierra MC; Echeverri AF; Posso-Osorio I; Suso JP; Tobón GJ
    J Clin Rheumatol; 2018 Apr; 24(3):158-159. PubMed ID: 29239927
    [No Abstract]   [Full Text] [Related]  

  • 12. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes.
    Yadlapati S; Efthimiou P
    Mod Rheumatol; 2016; 26(1):3-8. PubMed ID: 26140469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryopyrin-associated periodic syndrome (CAPS) in a patient with NLRP3 T348M mutation.
    Kreft B; Schlinsog AS; Wohlrab J
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1266-1268. PubMed ID: 30184330
    [No Abstract]   [Full Text] [Related]  

  • 17. Muckle-Wells cryopyrinopathy: complex phenotyping and response to therapy in a new multiplex kindred.
    Headley AP; Cordingley F; Hawkins PN; Riminton DS
    Inflammation; 2014 Apr; 37(2):396-401. PubMed ID: 24150829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
    Mueller SM; Itin P; Haeusermann P
    Dermatology; 2011; 223(2):113-8. PubMed ID: 21967869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muckle-Wells syndrome: a rare hereditary cryopyrin-associated periodic syndrome.
    Wakhlu A; Agarwal V; Saraswat A; Lachmann H
    Int J Rheum Dis; 2017 Nov; 20(11):1873-1875. PubMed ID: 26218404
    [No Abstract]   [Full Text] [Related]  

  • 20. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment.
    Kuemmerle-Deschner JB; Lohse P; Koetter I; Dannecker GE; Reess F; Ummenhofer K; Koch S; Tzaribachev N; Bialkowski A; Benseler SM
    Arthritis Res Ther; 2011; 13(6):R196. PubMed ID: 22146561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.